New registry monitors pregnancy safety after elagolix use
NCT ID NCT04464187
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 29 times
Summary
This study follows pregnant women who were exposed to elagolix (Orilissa or Oriahnn) for endometriosis or uterine fibroids, along with a comparison group of pregnant women not exposed. The goal is to track pregnancy outcomes, including birth defects and miscarriage. No treatment is given; participants fill out questionnaires during pregnancy and up to one year after delivery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Iqvia /Id# 240918
Durham, North Carolina, 27703-8426, United States
Conditions
Explore the condition pages connected to this study.